Skip to main content

Fady Malik

Analyst

Equibles does not estimate personal net worth.

About Fady Malik

Fady Malik has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Cytokinetics Inc on September 14, 2026. The companies whose calls Fady Malik spoke on are classified in the Healthcare sector.

Fady Malik on recent calls

“Yeah, I mean, we hear several reasons for potential switching from one to the other. perhaps difficulty in up titrating with residual symptoms or gradients, drops in EF that require treatment interruption, DDIs that are bothersome to the patient because of a particular medicine they would prefer to be on.”
Morgan Stanley 24th Annual Global Healthcare Conference ·
“The second quarter was an important period for our HCM portfolio, most notably with our announcement of positive top-line results from Acacia HCM, our pivotal phase three clinical trial in patients with symptomatic NHCM.”
Cytokinetics Q2 2026 Earnings Conference Call ·
“This morning, we were thrilled to report the top-line results from Acacia HCM. The trial met both of its dual primary endpoints, demonstrating statistically significant improvements from baseline to week 36 in both KCCQ clinical summary score and peak VO2 compared to placebo.”
Cytokinetics Q1 2026 Earnings Conference Call ·
“So, we went about the process of examining the effect of apicampin and non-obstructive HCM very deliberately. One of the challenges is, how do you dose the drug in NHCM?”
Barclays 28th Annual Global Healthcare Conference ·
“In support of the launch of MICORZO, our medical affairs organization continued to expand its engagement with the HCM community ahead of and now during our commercial launch.”
Cytokinetics Inc Q4 FY2025 Earnings Call ·

Company network

Recent activity